Masatoshi Kudo, MD, PhD

Articles

Future Directions for Treating uHCC: Triplet Therapy, Epigenetic Therapy, Cytotoxic Agents, and Antibody-Drug Conjugates (ADCs

November 29th 2024

Panelists discuss how ongoing trials and investigational agents, including the Checkmate 9DW study, could significantly influence future treatment approaches for unresectable hepatocellular carcinoma .

CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment

November 29th 2024

Panelists discuss key updates from the 2024 American Society of Clinical Oncology Annual Meeting and the European Society for Medical Oncology Congress 2024 regarding treatments for unresectable hepatocellular carcinoma (uHCC), including insights from the CheckMmate 9DW study on the use of nivolumab and ipilimumab, and their implications for sequencing and combination therapies in various lines of treatment.

Importance of Real-World Data in Supporting Treatment Options

November 29th 2024

Panelists discuss the insights from real-world data on the effectiveness of cabozantinib, regorafenib, and ramucirumab in second-line treatment for unresectable hepatocellular carcinoma, highlighting the differences between strict eligibility criteria and more flexible modified criteria in patient selection.

Discussion of RESORCE Trial

November 22nd 2024

Panelists discuss the data from the RESORCE trial, highlighting the efficacy of regorafenib in previously treated hepatocellular carcinoma, including primary trial results and insights on time to progression based on prior sorafenib treatment.

Real-World Treatment Data from the Phase 4 STELLAR Trial

November 22nd 2024

Panelists discuss the findings from the STELLAR trial, a phase 4 observational study presented at the European Society for Medical Oncology Congress 2024, which compares the efficacy of lenvatinib and sorafenib as first-line treatments for patients with advanced or unresectable hepatocellular carcinoma.

Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

November 15th 2024

Panelists discuss the CELESTIAL trial findings and their implications for second-line treatment strategies in Japan for patients with previously treated hepatocellular carcinoma.

CELESTIAL Sub-Group Discussion

November 15th 2024

Panelists discuss the subgroup analyses from the CELESTIAL trial, focusing on treatment outcomes for specific patient populations with previously treated hepatocellular carcinoma.

Choosing Second-Line Therapies: Considering First Line Therapy Received

November 8th 2024

Panelists discuss how to determine appropriate second-line and subsequent therapies for unresectable hepatocellular carcinoma after frontline treatment, emphasizing patient-specific factors and alternatives to clinical trial enrollment.

ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

November 8th 2024

Panelists discuss findings from the IMmbrave050 trial comparing atezolizumab plus bevacizumab to active surveillance in patients with high-risk hepatocellular carcinoma patients, highlighting the significance of follow-up for those at risk of recurrence post- curative treatment.

EMERALD-1 Study Results

October 25th 2024

Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.

Discussion and Summary

October 25th 2024

Panelists discuss the findings from the LEAP-012 study, which explores the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with Child-Pugh class A disease and intermediate-stage hepatocellular carcinoma.

LEAP-012 Study Results

October 25th 2024

Panelists discuss the results of the LEAP-012 study, highlighting the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with intermediate-stage hepatocellular carcinoma and Child-Pugh class A disease.

Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

October 25th 2024

Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.

Use of monotherapy (IO or TKI) or localized treatment in First Line

October 18th 2024

Panelists discuss the circumstances under which monotherapy with a tyrosine kinase inhibitor or immunotherapy would be preferred in the treatment of unresectable hepatocellular carcinoma.

Current Treatment in First Line – IO + TKI or IO + IO

October 18th 2024

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Treatment Decisions Based on BLCL Stage

October 7th 2024

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

October 7th 2024

Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.

Dr. Kudo on Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib

September 16th 2018

Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib versus sorafenib in unresectable hepatocellular carcinoma in Japan.

Dr. Kudo Discusses TACE Plus Sorafenib in HCC

February 15th 2018

Masatoshi Kudo, MD, PhD, Department of Gastroenterology and Hepatology, Kindai University, discusses the randomized phase II trial comparing transarterial chemoradiation (TACE) plus sorafenib (Nexavar) with TACE alone in patients with hepatocellular carcinoma (HCC).